Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M28.7Revenue (TTM) $M12.4Net Margin (%)-92.0Altman Z-Score-9.5
Enterprise Value $M-3.1EPS (TTM) $-1.1Operating Margin %-93.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.9Pre-tax Margin (%)-92.0Higher ROA y-yN
Price/Book0.710-y EBITDA Growth Rate %-21.8Quick Ratio4.2Cash flow > EarningsY
Price/Sales2.25-y EBITDA Growth Rate %-8.9Current Ratio4.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-22.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-26.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M11.4ROIC % (ttm)-126.5Gross Margin Increase y-yY

Gurus Latest Trades with VICL

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VICL is held by these investors:



VICL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramos Anthony AlanVP, Chief Accounting Officer 2017-03-27Sell4,250$2.1732.26view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2017-03-15Sell875$2.3124.24view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2017-02-10Sell4,500$2.2626.99view
SAMANT VIJAY BPresident & CEO 2017-02-01Sell3,750$2.1632.87view
SMITH LAWRENCE RUSSELLVP, Vaccine Research 2017-01-11Sell54$2.4815.73view
SAMANT VIJAY BPresident & CEO 2017-01-10Sell5,763$2.4517.14view
MERTON ROBERT CDirector 2016-12-22Sell4,000$2.2428.13view
MERTON ROBERT CDirector 2016-12-20Sell4,327$2.2129.86view
SAMANT VIJAY BPresident & CEO 2016-12-13Sell15,699$2.3920.08view
DOUGLAS R GORDONDirector 2016-12-12Sell10,078$2.3920.08view

Press Releases about VICL :

Quarterly/Annual Reports about VICL:

News about VICL:

Articles On GuruFocus.com
Vical to Provide Company Update at BIO Investor Forum Conference Oct 13 2017 
Vical Announces Completion of the Phase 3 ASP0113 CMV Vaccine Trial Oct 10 2017 
Vical Announces that its Antifungal VL-2397 is Eligible for Limited Use Indication Approval by FDA B Oct 02 2017 
Vical to Present at IDWeek and the 8th Trends in Medical Mycology Conferences Sep 28 2017 
Vical to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 06 2017 
Vical Reports Second Quarter 2017 Financial and Operational Results Aug 08 2017 
Vical Announces News Release and Conference Call Schedule for Second Quarter 2017 Financial Results Aug 01 2017 
Vical to Provide Company Update at the 2017 BIO International Convention Jun 15 2017 
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to P Jun 05 2017 
Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting May 23 2017 
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK